Clinical-stage immuno-oncology startup Arch Oncology will team up with pharmaceutical giant Merck & Co. (NYSE: MRK) as part of its ongoing clinical trials for its lead drug candidate. Arch Oncology said this week it has inked a clinical trial collaboration and supply agreement with New Jersey-based Merck. The partnership involves assessing Arch Oncology’s lead drug candidate, AO-176, in combination with Merck’s cancer drug KEYTRUDA for patients with select solid tumors…
